Tandem Diabetes Care (NASDAQ:TNDM) Price Target Cut to $33.00 by Analysts at Robert W. Baird

Tandem Diabetes Care (NASDAQ:TNDM) had its price objective reduced by Robert W. Baird from $37.00 to $33.00 in a research note issued to investors on Thursday,Benzinga reports. Robert W. Baird currently has a neutral rating on the medical device company’s stock.

TNDM has been the topic of a number of other research reports. Canaccord Genuity Group restated a “buy” rating and issued a $63.00 price target on shares of Tandem Diabetes Care in a research report on Wednesday. Citigroup dropped their price target on shares of Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Barclays boosted their price target on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Morgan Stanley upgraded shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price target on the stock in a research report on Monday, December 2nd. Finally, Sanford C. Bernstein started coverage on shares of Tandem Diabetes Care in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $53.38.

Tandem Diabetes Care Stock Down 35.2 %

Shares of NASDAQ TNDM opened at $21.75 on Thursday. The company has a market capitalization of $1.43 billion, a P/E ratio of -11.27 and a beta of 1.32. Tandem Diabetes Care has a 52-week low of $21.43 and a 52-week high of $53.69. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The company’s 50 day moving average price is $35.45 and its 200-day moving average price is $36.62.

Hedge Funds Weigh In On Tandem Diabetes Care

A number of hedge funds have recently bought and sold shares of TNDM. Brooklyn Investment Group purchased a new position in Tandem Diabetes Care during the 3rd quarter worth $28,000. Assetmark Inc. purchased a new position in Tandem Diabetes Care during the 3rd quarter worth $29,000. AlphaQuest LLC boosted its holdings in Tandem Diabetes Care by 138.7% during the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock worth $34,000 after acquiring an additional 541 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in Tandem Diabetes Care by 195.8% during the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock worth $41,000 after acquiring an additional 748 shares during the last quarter. Finally, McIlrath & Eck LLC purchased a new position in shares of Tandem Diabetes Care in the 3rd quarter worth about $52,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.